Published on 1st March 2013
A recently published retrospective, quasi-experimental study from Manian et al. shows the impact of hydrogen peroxide vapor (HPV) technology on C. difficile-associated diarrhea.
Published on 18th February 2013
Threats against civilian and private security vehicles using airborne contaminants, such as car-jacking and kidnap attempts, can now be protected against following the launch of the new Bioquell LEAF system.
Published on 31st December 2012
A new study conducted by infection control experts at Johns Hopkins Hospital demonstrates that patients admitted to hospital rooms decontaminated using Bioquell hydrogen peroxide vapor technology, rather than standard cleaning protocols, were significantly less likely to acquire multidrug-resistant organisms (MDROs), or so-called hospital superbugs. The study is published in the January issue of Clinical Infectious Diseases.
Published on 20th August 2012
In the fight against superbug outbreaks, the use of a bundle of infection control measures, including the use of hydrogen peroxide vapor (HPV) technology, have significantly reduced the incidence of nosocomial MRSA and Acinetobactor baumannii in one of Europe's leading burns units.
Published on 13th April 2012
Latest comparative research shows that hydrogen peroxide vapor (HPV) technology is more effective at reducing bacterial contamination in hospitals than ultraviolet light-based (UVC) systems.
The head-to-head study published in Infection Control and Hospital Epidemiology, was conducted by leading infection control practitioners at the Hospital of Saint Raphael and Yale University School of Medicine, both in New Haven, Connecticut. Their results showed that Bioquell’s HPV was significantly more effective for reducing biological contamination, including spores, in patient rooms compared with a UVC system. This was especially evident for areas that were out of direct line of sight of the UVC system. Overall, half of the surfaces contaminated with bacteria before exposure to UVC remained contaminated after UVC exposure.
Published on 7th March 2012
In the United States, healthcare associated infections (HAIs) and their cost to the healthcare system are staggering. The CDC estimates that approximately 1 in every 20 hospitalized patients will contract an HAI. Cost estimates range upward of $40 billion dollars annually in the fight against HAIs. Recently released CDC statistics show infection rates and deaths from HAIs climbing. Deaths attributed with Clostridium difficile infection rates alone have jumped to a range of 14,000 per year. To help in the fight against HAIs, Bioquell has launched its educational Bug Stoppers campaign.
Published on 5th March 2012
A recent independent study confirms hydrogen peroxide vapor technology as superior to the aerosolized hydrogen peroxide process. A team at St. George’s Hospital, London, UK, unquestionably established that hydrogen peroxide vapor (HPV) technology from Bioquell is faster, safer, and more effective for room biodecontamination than aerosolized hydrogen peroxide (aHP).
Published on 7th February 2012
The latest generation hydrogen peroxide bio-decontamination technology from Bioquell has now achieved Australian C-Tick approval. The C-Tick mark provides assurance that products have been tested to the appropriate standards for conformity to the EMC (Electro Magnetic Compatibility) and Radio Telecommunications standards by a registered testing laboratory.
Published on 18th January 2012
Bioquell announces that it has been awarded a £1.2 million development contract relating to the new vehicle being developed by General Dynamics UK for the UK Ministry of Defense.